Your shopping cart is currently empty

ML-SA5 is a MCOLN1 agonist that blocks autophagic flux by disrupting fusion between autophagosomes and lysosomes.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $33 | In Stock | In Stock | |
| 5 mg | $76 | In Stock | In Stock | |
| 10 mg | $133 | In Stock | In Stock | |
| 25 mg | $283 | In Stock | In Stock | |
| 50 mg | $455 | In Stock | In Stock | |
| 100 mg | $672 | In Stock | In Stock | |
| 1 mL x 10 mM (in DMSO) | $77 | In Stock | In Stock |
| Description | ML-SA5 is a MCOLN1 agonist that blocks autophagic flux by disrupting fusion between autophagosomes and lysosomes. |
| In vitro | METHODS: 0.05 or 0.1 μM ML-SA5 was used to treat HeLa cells 1 hour and 4 hours after the application of agonists, and the LC3-II levels in HeLa cells were observed. RESULTS ML-SA5 significantly increased the LC3-II levels. ML-SA5 regulates the LC3-II levels by stimulating the activity of MCOLN1 channels. [1] METHODS: Vero cells stably expressing GFP-Lamp1 were transfected with pStrep-mCherry-CvpE. Twenty hours after transfection, cells were treated with DMSO or ML-SA5 (30 μM) for 4 hours. Then, cells were fixed and nucleic acids were stained with DAPI. RESULTS ML-SA5 treatment completely blocked CvpE-induced cytoplasmic vacuolization. [2] |
| In vivo | METHODS: Patu 8988 t cells were injected into the subcutaneous tissue of nude mice, and ML-SA5 (5 μM) was injected into solid tumors daily. Tumor volume was measured daily, and immunohistochemistry and immunoblot analysis were performed after death of mice. RESULTS Administration of ML-SA5 profoundly promoted the survival of Patu 8988 t xenograft mice and inhibited tumor growth. [1] |
| Molecular Weight | 457.99 |
| Formula | C19H24ClN3O4S2 |
| Cas No. | 2418670-70-7 |
| Smiles | CN(C)S(=O)(=O)c1ccc(cc1)S(=O)(=O)Nc1cccc(Cl)c1N1CCCCC1 |
| Relative Density. | 1.395 g/cm3 (Predicted) |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 122.5 mg/mL (267.47 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (4.37 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.